 |
|
Physicians’ perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey
Ran-hui Cha, Su Hyun Kim, Eun Hui Bae, Mina Yu, Beom Soon Choi, Hoon Young Choi, Sun Woo Kang, Jungho Shin, Sang Youb Han, Chul Woo Yang, Duk-Hee Kang
Kidney Res Clin Pract. 2019;38(3):373-381. Published online 2019 Sep 30 DOI: https://doi.org/10.23876/j.krcp.19.007
|
|
Citations to this article as recorded by
 Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3–5 patients with asymptomatic hyperuricemia: a network meta-analysis
Jiaojiao Chen, Yanyun Zhang, Yinglin Wang, Lu Chen
Renal Failure.2025;[Epub] CrossRef Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients
Yun Kyu Oh, Hayne Cho Park, Hyunjin Ryu, Yong-Chul Kim, Kook-Hwan Oh
The Korean Journal of Internal Medicine.2021; 36(4): 767. CrossRef Hyperuricemia in Renal patients: Treat or not to treat
Abbasi Muhammad Tanzeel, Asghar Muhammad Rashid, Bashir Khuram, Hashmi Muhammad Nauman
Archives of Clinical Nephrology.2021; : 050. CrossRef Renal effects of uric acid: hyperuricemia and hypouricemia
Jung Hwan Park, Yong-Il Jo, Jong-Ho Lee
The Korean Journal of Internal Medicine.2020; 35(6): 1291. CrossRef To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease
Dong Ho Shin
Kidney Research and Clinical Practice.2019; 38(3): 257. CrossRef
|